Evaluation of the axilla and current standards of pathological work-up

Breast

Volumn 10, Issue SUPPL. 3, 2001, Pages 69-73

  Viale, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPITHELIAL MEMBRANE ANTIGEN; MESSENGER RNA;

ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER STAGING; CANCER THERAPY; CONTROLLED STUDY; EVALUATION; FEMALE; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INTRAOPERATIVE PERIOD; LYMPH NODE METASTASIS; MOLECULAR BIOLOGY; MORBIDITY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; STANDARD;

EID: 0034920873     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(16)30012-1     Document Type: Article

References (31)

1. Selective lymphadenectomy: Emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma
2. Sentinel lymphadenectomy for patients with clinical Stage I melanoma
3. Location of sentinel lymph nodes in patients with cutaneous melanoma: New insights into lymphatic anatomy
4. Lymphatic mapping and sentinel lymphadenectomy for breast cancer
5. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer
6. Sentinel lymphadenectomy in breast cancer
7. Sentinel lymphadenectomy for breast cancer in a community managed care setting
8. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes
9. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma
10. Sentinel lymph node biopsy and axillary dissection in breast cancer: Results in a large series
11. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients
12. Assessment of morbidity from complete axillary dissection
13. Complications of axillary lymph node dissection for carcinoma of the breast: A report based on a patients survey
14. Complications of level I and II axillary dissection in the treatment of carcinoma of the breast
15. Physical and psychological morbidity after axillary lymph node dissection for breast cancer
16. Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma
17. Lymphatic mapping with sentinel lymph node biopsy in patients with breast cancers < 1 centimeter (T1a-T1b)
18. Sentinel lymph node biopsy: Strategies for pathologic examination of the specimen
19. Prognostic importance of occult axillary micrometastases from breast cancers
20. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer
21. Benign transport of breast epithelium into axillary lymph nodes after biopsy
22. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma
23. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients
24. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma
25. Cytokeratin (CK)-immunoreactive cells of human lymph nodes and spleen in normal and pathologic conditions. An immunocytochemical study
26. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction
27. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUCI mRNA and keratin 19 mRNA amplification
28. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients
29. Clinical significance of micrometastases in axillary lymph nodes assessed by reverse transcription-polymerase chain reaction in breast cancer patients
30. Sentinel lymph node biopsy with metastasis: Can axillary dissection be avoided in some patients with breast cancer
31. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?